Abiraterone acetate: A novel therapeutic option in hormonorefractory prostate cancer;Una nuova opzione terapeutica nel carcinoma prostatico ormonorefrattario

Recenti Progressi in Medicina

Volumn 103, Issue 2, 2012, Pages 74-78

  Turitto, Giacinto ^a   Di Bisceglie, Maurizio ^a   Moraca, Lucia ^a   Sasso, Nicola ^a   Sepede, Carmela ^a   Suriano, Angela ^a   Romito, Sante ^a  

^a Struttura Complessa Oncologia Medica   (Italy)

Author keywords

Abiraterone acetate; Hormonal therapy; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; CYTOCHROME P450 17; CYTOCHROME P450 17A1; DOCETAXEL; MINERALOCORTICOID; PLACEBO; PREDNISONE; SIPULEUCEL T; TESTOSTERONE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; DRUG TOLERABILITY; EDEMA; ENZYME INHIBITION; FLUID RETENTION; HUMAN; HYPERTENSION; HYPOKALEMIA; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; TESTOSTERONE SYNTHESIS;

ANDROSTENOLS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PREDNISONE; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TREATMENT OUTCOME;

EID: 84859029862     PISSN: 00341193     EISSN: 20381840     Source Type: Journal    
DOI: 10.1701/1045.11391     Document Type: Review

References (18)

1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone ormitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12. (Pubitemid 39315317)
2. Geller J, Albert JD, Nachtsheim DA, Loza D. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 1984; 132: 693-6. (Pubitemid 14017006)
3. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-25.
4. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-54.
5. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164: 217-27. (Pubitemid 38364606)
6. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-61. (Pubitemid 46211563)
7. Trachtenberg J, Halpern N, Pont A. Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 1983; 130: 152-3. (Pubitemid 13074092)
8. Auchus RJ. Overview of dehydroepiandrosterone biosynthesis. Semin Reprod Med 2004; 22: 281-8.
9. Miller WL, Auchus RJ, Geller DH. The regulation of 17,20 lyase activity. Steroids 1997; 62: 133-42.
10. Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995; 38: 2463-71.
11. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005; 96: 1241-6. (Pubitemid 41743917)
12. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer (CRPC) commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-71.
13. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 1481-8.
14. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8.
15. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-95.
16. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-501.
17. de Bono JS, Logothetis CJ, Molina A, et al.; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
18. Fizazi K et al. ESMO 2011 abstract 7000 (oral presentation).